Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.

Trial Details

NCT ID
NCT06515262
Phase
NA
Sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Anti-BCMA-GPRC5D CAR-T cells infusion
Locations (sample)
  • Kunming, Kunming, Yunnan, China|25.03889,102.71833

Key Eligibility Criteria

  • The patient or his/her guardian understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and t…
  • Age 18-75 years old, gender unlimited;
  • Diagnosed as Multiple Myeloma (MM) according to the international standard for multiple myeloma (IMWG);
  • The presence of measurable disease at screening meets one of the following criteria:Serum M-protein ≥ 1.0 g/dL or Urine M-protein ≥ 200 mg/24h or d…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →